Aims:To evaluate OS and EFS of paediatric sarcoma patients with an interest in comparing metastatic cases with non-metastatic cases, and compiling statistics on treatment methods.Methods: Information was obtained from patient notes in the Schiehallion ward. These contained information about diagnosis, treatment, prognostic indicators, and outcomes for each patient.Results: 56 patients, 2001 -2008 ; age range: 4-16; OS = 64%, EFS = 55%; Primary site of disease: Femur (47%), Tibia (41%), Humerus (5.5%), Scapula (5.5%), Other (1%); Metastatic Rate = 27% (OS = 0%). Ewing's sarcoma: 24 patients, 10 age range: 1-16 ; OS = 71%, EFS = 58%; Primary site of disease: Pelvis (29%), Femur (22%), Paraspinal (16%), Chest Wall (10%), Tibia (10%), Other (13%); Metastatic Rate = 21% (OS = 40%; EFS = 40%); Alveolar rhabdomyosarcoma: 10 patients; OS= 80%, EFS = 60%; Metastatic Rate = 20% (OS = 100%; EFS = 100%). Embryonal rhabdomyosarcoma: 11 patients; OS = 73%, EFS = 73%; Metastatic Rate = 0%. Conclusions:Our results reflect access to an experienced and innovative paediatric sarcoma service with close links to a national Sarcoma MDT. The data falls in line with other studies in terms of age of onset, location of primary tumour, metastatic rate, site of metastases, and prognosis for all cancer types. Limb salvage surgery is greatly favoured over amputation for both osteosarcoma and Ewing's sarcoma. Females have a more favourable prognosis in osteosarcoma and a slightly poorer prognosis in Ewing's sarcoma. Yorkhill's overall survival rates are currently better than the UK-wide statistic for three of the four tumours examined.